Article · 5 May 2025
Conference abstract
PK/PD modeling and trial simulation for everyone
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Nowadays it is rare to see any FDA submission package without a Pharmacokinetics/Pharmacodynamics modeling component where some clinical trials were designed based on simulation. The current workflow is that an expert modeler provide model outputs and simulation about scenarios that he thinks are important to emulate future trials and decisions. Then, the decision maker might then ask for new more relevant scenarios to the current situation. This decision process is iterative where one simulated scenario might warrant another question/scenario that need to be tested until we reach a satisfactory decision. As such this involves sveral cycles of back and forth. All this results in bottlenecks cycles where the decision maker is waiting for simualtion results and where simulation scientists are waiting for decision maker to give them more scenarios to test. Why is this ? The simulation workflow is so complicated that only the person who built the underlying models and simulation scenarios can get useful answers. However, recent technological advances has enabled simulation scientists to build specialized user interfaces that enable decision makers to be part of the design team and ask questions and get answers on the fly. Today this is possible using web based responsive user interface A successful simulation exercice involve a mathematical modeler (e.g.pharmacometrician), a clinical trial expert, a therapeutic area expert (or a clinician) a computational/web developer expert and the clinical development decision maker. An example of the development of such an app for Tuberculosis will be demoed.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Book review · 30 Dec 2024
Integrating Digital Twins with AI to Enhance Clinical Trial Simulations and Decision-Making
Conference abstract · 11 Sep 2017
Integration of clinical study data to support trial simulation activities
Conference abstract · 7 Dec 2015
Computerized Simulation of Anti-HIV Drug Synergy in Vitro and in Clinical Trials Using the Chou-Talalay Combination Index Method
Research article · 2015
Differences in Sample Size Requirements of Statistical Methods Involved in Clinical Trials with Baseline Imbalance Demonstrated and Quantified: A Simulation Study
More from this journal
The newest in Journal of Clinical & Experimental Pharmacology.
Article · 9 Nov 2026
Balancing Efficacy and Tolerability in Nasal Decongestion: A Rationale for the Oxymetazoline and Dexpanthenol Combination
Article · 23 Feb 2026
A Thorough Overview of Polycystic Ovary Syndrome (PCOS) in Female Rats
Article · 19 Dec 2025
Theoretical Pharmacology: Understanding Drug Action Through Models and Principles
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pharmacology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Mohamad Samer Mouksassi”

